Targeting advanced urothelial carcinoma-developing strategies. Issue 3 (May 2019)

• Record Type: Journal Article
• Authors: Alhalabi, Omar; Rafei, Hind; Shah, Amishi; Siefker-Radtke, Arlene; Campbell, Matthew; Gao, Jianjun
• Is Part Of: Current opinion in oncology. Volume 31:Issue 3(2019:May)
• Publication Date: 2019-05
• Subjects: antibody–drug conjugates -- immune checkpoint inhibitors -- targeted therapy -- urothelial carcinoma; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000532
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: Advanced urothelial carcinoma is a heterogeneous disease with high burden of morbidity, mortality, and cost. Significant progress has been made in understanding the biology of the disease and the development of immunotherapies and targeted therapies. In this review, we summarize the current and future therapeutic approaches in the management of urothelial carcinoma. Recent findings: Advances in immune checkpoint inhibitors resulted in the Food and Drug Administration (FDA) approvals of atezolizumab in 2016, and pembrolizumab, avelumab, durvalumab, and nivolumab in 2017 for the treatment of advanced urothelial carcinoma. More recently, development of inhibitors targeting the fibroblast growth factor receptor genetic alterations and antibody–drug conjugates targeting specific cell surface antigens (trop2, nectin4, and SLITRK6) resulted in several FDA breakthrough designations for urothelial carcinoma. Conclusion: The development of novel therapies targeting the immune and molecular pathways of advanced urothelial carcinoma is promising for the improvement of outcomes in this lethal disease. Ongoing efforts are poised to optimize therapeutic options in the post-chemotherapy arena. In the era of precision medicine, the future of urothelial carcinoma lies in using less cytotoxic chemotherapy, more targeted therapy and immunotherapy, and possibly a combination of these therapeutic approaches.